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ABSTRACT: Background: Optimal treatment for locally advanced squa-
mous cell carcinoma of the oropharynx (SCCOP) is not well defined. Here
we retrospectively compare survival and toxicities from 2 different organ
preservation protocols.
Methods. The matched dataset consisted of 35 patients from each trial
matched for age, stage, smoking, and tumor human papillomavirus
(HPV) status. Patients in the University of Michigan Cancer Center
(UMCC) trial 9921 were treated with induction chemotherapy (IC)
followed by high-dose cisplatin and radiation in responders or surgery in
nonresponders. Patients in the UMCC trial 0221 were treated with
weekly carboplatin and paclitaxel and radiation.
Results. Survival was comparable for both studies and did not differ
significantly across each trial after stratifying by HPV status. Grade 3
and 4 toxicities were more frequent in UMCC 9921. At 6 months post-
treatment, gastrostomy tube (G-tube) dependence was not statistically
different.
Conclusion. These data suggest that survival outcomes in patients with
locally advanced SCCOP are not compromised with weekly chemother-
apy and radiation therapy, and such treatment is generally more
tolerable.VC 2013 Wiley Periodicals, Inc. Head Neck 36: 617–623, 2014
KEY WORDS: chemoradiation, oropharynx, HPV, weekly, toxicity
INTRODUCTION
Squamous cell carcinoma of the head and neck accounts
for approximately 3% to 4% of all new cancer diagnoses
each year.1 Approximately 49,260 new cases of SCC of
the oral cavity, oropharynx, and larynx were diagnosed in
the United States in 2010,2 and approximately 60% of
these patients present with locally advanced disease.2
Such patients are primarily treated with combined chemo-
radiotherapy (CRT) as a means of organ preservation.3,4
In particular, definitive CRT offers excellent survival and
functional results for patients with SCC of the oropharynx
(SCCOP), especially those with human papillomavirus
(HPV)-positive disease.5 As the number of HPV-related
oropharyngeal cancers continues to rise, there is growing
concern that this patient population is perhaps being over-
treated. Work is currently underway to find treatment
strategies that provide excellent survival but with lesser
toxicity.
Cisplatin-based CRT regimens remain the standard of
care for the majority of patients with locally advanced
SCCOP.3,4 Carboplatin has been used alone or in combina-
tion with other cytotoxic chemotherapies in conjunction
with radiation to treat oropharyngeal SCC with outcomes
similar to those of cisplatin-based regimens, although no
large randomized studies have compared the efficacy of
carboplatin and radiation with that of high-dose cisplatin
and radiotherapy.6–8 Studies combining weekly platinum
and taxanes with radiation demonstrate similar efficacy to
high-dose cisplatin-containing regimens, but, again, such
combinations have not been compared head-to-head. These
weekly CRT strategies do, however, seem to be more tol-
erable than their high-dose platinum counterparts.9–11
To evaluate for efficacy and tolerability, we compared a
weekly carboplatin-radiotherapy and paclitaxel-radiotherapy
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regimen against a chemoselection regimen utilizing high-
dose cisplatin and radiotherapy after 1 cycle of induction
chemotherapy (IC).
MATERIALS AND METHODS
Patient populations
We retrospectively conducted pairwise matching of
patients from 2 prospective, single arm phase II trials that
used different treatment strategies for stage III/IV SCCOP
(University of Michigan Cancer Center [UMCC] trial
9921 and UMCC trial 0221). Our goal was to compare
survival outcomes and toxicities of these treatment strat-
egies. Both protocols enrolled patients with histologically
confirmed, previously untreated stage III or IV SCCOP
who were candidates for treatment with curative intent.
All patients had a Karnofsky performance status of at
least 60%. UMCC 9921 protocol enrolled only patients
who were candidates for complete surgical resection,
whereas UMCC 0221 eligibility did not require surgical
resectability. However, our analysis only included those
patients who were deemed surgically resectable.
Treatment protocols
The schemata for both trials are shown in Figure 1.
UMCC 9921 trial6 enrolled patients from January 1,
2000, through November 30, 2002. It used chemoselec-
tion with 1 cycle of IC with 5-fluorouracil at 1000 mg/
m2/day by continuous infusion, days 1 through 5, plus ei-
ther cisplatin at 100 mg/m2 (n 5 31) or carboplatin (n 5
4) dosed at an area under curve (AUC) of 6 on day 1.
Patients were then assessed by direct laryngoscopy 3
weeks after IC. Responders (patients with greater than
50% reduction in bidimensional product of the primary
tumor area on direct laryngoscopy) were then treated with
definitive concurrent CRT, utilizing intensity-modulated
radiation therapy (IMRT) in daily 2-Gy fractions 5 days a
week to a total of 70 Gy to areas of gross disease. Radia-
tion was administered concurrently with cisplatin (100
mg/m2) or carboplatin (AUC 6) on days 1, 22, and 43.
Tissue volumes at risk of harboring subclinical disease
received 59 to 63 Gy at 1.7 to 1.8/fraction. Nonrespond-
ers (patients with 50% or less reduction in bidimensional
product of the primary tumor area) underwent definitive
surgery followed by adjuvant radiation (66 Gy). Eight
weeks after completion of CRT, direct laryngoscopy was
performed. Patients without residual disease were offered
adjuvant paclitaxel (2 cycles at 175 mg/m2 every 21
days). Those with residual disease underwent surgical
resection of the primary tumor with an ipsilateral neck
dissection. Cervical lymph nodes of 3 cm or greater at
the time of diagnosis were among the indications for
planned neck dissection.6 Posttherapy evaluations con-
sisted of clinical examinations every 6 to 8 weeks and
positron emission tomography (PET)-CT imaging at 3
and 12 months. UMCC 0221 trial9 used IMRT (70 Gy
delivered in 2 Gy fractions over 7 weeks) concurrently
with weekly chemotherapy, carboplatin (AUC 1) plus
paclitaxel (30 mg/m2). IMRT planning objectives
included sparing of the swallowing structures (ie, pharyn-
geal constrictor muscles, esophagus, glottic and supraglot-
tic larynx, major salivary glands, and oral cavity).
Posttherapy evaluations consisted of clinical examinations
every 6 to 8 weeks and PET-CT imaging at 3 and 12
months.
Human papillomavirus testing
HPV testing on pretreatment biopsies was performed
using HPV polymerase chain reaction–mass array, which
detects and identifies 15 high-risk HPV subtypes using
FIGURE 1. Patients whose outcomes are compared were treated according to University of Michigan Cancer Center (UMCC) 9921 trial or the UMCC
0221 trial protocols.
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type-specific, multiplex, competitive polymerase chain
reaction, and single base extension followed by matrix-
assisted laser desorption ionization-time of flight mass
spectrometry analysis, as previously described.12
Statistical analysis
Propensity score matching of patients treated on these 2
protocols yielded 35 pairs of subjects (70 patients)
matched for age, clinical stage, smoking status (never
smoked, past smoker, or current smoker) and tumor HPV
status. Primary endpoints were overall survival (OS),
defined as duration of survival from date of enrollment to
date of death from any cause, and disease-specific sur-
vival (DSS), which was defined as time from enrollment
to date of death from local recurrence, distant metastasis,
or treatment-related mortality. Deaths from other causes
were treated as censored observations for DSS analysis.
Kaplan–Meier estimates were calculated for OS and DSS.
The results from univariate Cox proportional hazards
models and multivariable Cox models chosen from a
backward selection process are presented here. The
matched datasets were adjusted using multivariate statis-
tics and cluster analyses to account for the correlated na-
ture of the matched pairs. Secondary endpoints included
treatment-induced toxicities and persistent gastrostomy
(G)-tube use beyond 6 months. Generalized estimating
equation models were used to analyze these dichotomous
outcomes adjusting for the matched nature of the dataset.
Adjusted analysis was performed for the matched design
and obtained similar results to unadjusted analysis. For all
statistical analyses, a p value of < .05 was considered
significant. Of the patients treated on the UMCC 9921
protocol, 3 underwent early surgery because of the failure
of IC. The analysis shown in this article includes all
patients; a sensitivity analysis removing the 3 surgery
patients is described as well.
Both UMCC 9921 and UMCC 0221 trials were
reviewed and approved by the institutional review board,
and were in accordance with the Helsinki Declaration of
1975, as revised in 1983.
RESULTS
Comparability of matched patients
Survival outcomes and toxicities were compared among
the 2 trials. To assure a meaningful comparison, we
matched patients by study cohort for age, smoking status,
and tumor HPV status. In total, 70 patients (35 from each
trial) were matched. The patients were well balanced
between the 0221 and 9921 cohorts (Table 1). All patients
included in the analysis had an Eastern Cooperative
Oncology Group (ECOG) performance status of 0 or 1,
but there were more ECOG 0 patients in the 9921 than
the 0221 group (ECOG 0, 86% vs 63%; ECOG 1, 14%
vs 37%; p 5 .05). Both groups enrolled predominantly
male patients, although the proportion of women was
higher in the 9921 trial (29% vs 9%; p 5 .03). IC was
unsuccessful in 3 patients in the 9921 group, and there-
fore they required early surgery.
Survival outcomes
In the univariate analysis (Figure 2A), survival at 36
months was superior in the UMCC 0221 group compared
TABLE 1. Demographics of the matched patients. Thirty-five pairs of
patients (70 patients) matched for age, clinical stage, smoking
status, and tumor human papillomavirus status.
UMCC 9921
(n 5 35)
UMCC 0221
(n 5 35) p value
Age mean (SD) 55.0 (7.6) 55.0 (7.9) .99
Stage no. (%) 1
Stage 3 7 (20) 7 (20)
Stage 4 28 (80) 28 (80)
Sex no. (%) .03
Female 10 (29) 3 (9)
Male 25 (71) 32 (91)
ECOG .05
0 30 (86) 22 (63)
1 5 (14) 13 (37)
Smoking status no. (%) 1
Never 8 (23) 8 (23)
Past 14 (40) 14 (40)
Current 13 (37) 13 (37)
HPV 1
Positive 27 (77) 27 (77)
Negative 8 (23) 8 (23)
Abbreviations: UMCC, University of Michigan Cancer Center; ECOG, Eastern Cooperative
Oncology Group; HPV, human papillomavirus.
FIGURE 2. Survival at 3 years. (A) Overall survival. (B) Disease-
specific survival. [Color figure can be viewed in the online issue,
which is available at wileyonlinelibrary.com.]
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to the UMCC 9921 group (88% vs 71%; hazard ratio
[HR], 0.35; 95% confidence interval [CI], 0.14–0.89).
However, this difference was not confirmed on multivari-
ate analysis (Table 2). Another factor that predicted
improved survival in the univariate but not the multivari-
ate analysis was past smoker versus current smoker status
(HR, 0.083; 95% CI, 0.012–0.59). Our analysis confirmed
that HPV-positive status was associated with superior sur-
vival (multivariate model, HR, 0.26; 95% CI, 0.09–0.72).
DSS at 3 years was superior in the UMCC 0221 group in
the univariate (97% vs 81%) but not within the multivari-
ate analysis (Figure 2B).
The favorable prognostic value of HPV-positive status
was seen for patients in both study cohorts (Figure 3).
Comparing HPV-positive patients in both protocols, a
trend toward an association between improved survival
and UMCC 0221 protocol was observed within the HPV-
positive group (p 5 .06). The best survival was seen in
HPV-positive patients in UMCC 0221, whereas the worst
survival was observed in HPV-negative patients treated
on UMCC 9921 (p 5 .01). Previously published analyses
reported 70.4% OS and 75.8% DSS rates at 4 years in
UMCC 9921. At a median follow-up of 36 months, 3-
year disease-free and locoregional recurrence–free surviv-
als were reported as 88% and 96%, respectively, in
UMCC 0221. Exclusion of the 3 patients on the 9921
protocol who underwent early surgery did not affect the
OS outcomes (data not shown).
Comparison of toxicities
Toxicities (all grades) were overall more prevalent in
the 9921 group with the exception of weakness/fatigue,
which was somewhat more frequent in the 0221 group
(54% vs 40%, respectively; p 5 .09; Table 3). Among
grade III and IV toxicities, leukopenia, neutropenia, and
mucositis were more prevalent in the 9921 group.
Persistent G-tube dependence for longer than 6 months
was seen more often in the 9921 than the 0221 trial
patients, albeit it was not statistically significant (26% vs
6%; p 5 .05). This did not vary by HPV status (Table 4).
When the 3 early surgery patients from the 9921 protocol
were excluded from analysis, the difference across proto-
cols became statistically significant (p 5 .04).
DISCUSSION
Weekly administration of platinum-based chemotherapy
with radiation, while potentially allowing for lower
toxicity,13 has not been established as the standard of
care for patients with locally advanced squamous cell car-
cinoma of the head and neck. Furthermore, there are no
randomized trials demonstrating the benefit of taxane-
based CRT regimens, with or without platinum, over
bolus regimens of cisplatin with radiation or even radio-
therapy alone. Our center has studied methods of organ
preservation in patients with oropharyngeal cancer utiliz-
ing both a standard high-dose cisplatin chemoradiation
regimen and a weekly carboplatin and paclitaxel chemo-
radiation regimen, both with similar outcomes. Given the
lack of randomized data comparing weekly to bolus-dose
platinum CRT regimens, we elected to compare these 2
trials to evaluate efficacy and toxicity. The results of our
pairwise-matched analysis are interesting, as they imply
that our less toxic organ-preservation approach with
weekly chemotherapy and radiation provides similar clini-
cal efficacy to that of high-dose cisplatin and radiation.
Bolus-dose cisplatin chemoradiation regimens incur sig-
nificant toxicities,14–16 whereas weekly chemoradiation is
better tolerated overall, with lower incidence of side
effects, as seen in our study and other trials utilizing
weekly CRT.10,11,17,18 Radiation therapy contributes
extensively to the toxicity observed in these patients;
however, weekly chemotherapy itself is usually well tol-
erated. We specifically report on long-term G-tube de-
pendence, as this is a major impediment to regaining
quality of life for many patients with head and neck
TABLE 2. Comparison of overall survival in the pairwise-matched datasets.
Predictor
Univariate
model p value
HR in univariate
Cox model (95% CI)
Multivariable
model p value
HR in multivariable
model (95% CI)
Protocol (UMCC 0221 vs UMCC 9921) .027 0.35 (0.14–0.89) NS
Female vs male .0003 5.48 (2.16–13.92) .0054 3.83 (1.49–9.86)
Stage (4 vs 3) .62 1.43 (0.35–5.86) NS
ECOG (1 vs 0) .81 0.86 (0.24–3.07) NS
Never vs current smoker .34 0.47 (0.10–2.25) NS
Past vs current smoker .013 0.083 (0.012–0.59) NS
HPV status (positive vs negative) .001 0.19 (0.068–0.51) .0094 0.26 (0.09–0.72)
Abbreviations: HR, hazard ratio; CI, confidence interval; UMCC; University of Michigan Cancer Center; NS, not significant; ECOG, Eastern Cooperative Oncology Group; HPV, human papillomavirus.
FIGURE 3. Overall survival by treatment protocol and human pap-
illomavirus (HPV) status of the tumor. [Color figure can be viewed
in the online issue, which is available at wileyonlinelibrary.com.]
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cancers. In our experience, there was a decreased long-
term G-tube dependence with weekly CRT.
Although our data were not randomized or prospective,
our findings are important as we are the first to report
outcomes of a comparison of a weekly versus a bolus-
dose CRT regimen for locally advanced SCCOP. Because
the ideal weekly regimen has yet to be identified, we
believe that our carboplatin/paclitaxel treatment schedule
is acceptable given its overall tolerability. Several phase
II trials have utilized either carboplatin or cisplatin with
paclitaxel, but no randomized comparisons of weekly
CRT regimens have been reported (Table 5). Because of
the vast heterogeneity among these trials, it is difficult to
make definitive comparisons. Our study, for instance,
evaluated only patients with oropharyngeal primaries,
whereas most others included multiple primary sites with
variability in terms of surgical resectability. Furthermore,
ours was the only trial to evaluate chemoradiation regi-
mens in the setting of HPV other than Suntharalingam et
al,19 which included cetuximab and reported high rates of
mucositis. Additionally, there is a wide variability in the
chemotherapy regimens administered and the type of radi-
ation delivered amongst these studies.11,20–22
A number of studies utilized a lower dose, weekly
cisplatin, either alone or in combination with other
agents.17,18,23 However, no comparisons with high-dose
cisplatin are available.
HPV is now an important prognostic biomarker in
SCCOP. Current data demonstrates 3-year survival rates
of >80% in patients with HPV-positive tumors when
treated with combined CRT.5 As long-term survival is
more likely achievable in these patients, freedom from
long-term and late side effects is an emerging
goal. Efforts are currently underway to reduce toxicity
without undermining the effect of CRT. RTOG 1016
(NCT01302834) is a large randomized trial enrolling
patients who are HPV-positive and have oropharyngeal
cancer to treatment with both cetuximab and accelerated-
fractionation radiotherapy versus 2 cycles of high-dose
cisplatin with accelerated-fractionation radiotherapy. This
study is rapidly accruing patients and plans to enroll close
to 800 subjects. The ECOG has now completed a dose
de-escalation study (ECOG 1308), whereby HPV-associ-
ated oropharyngeal tumors that were complete responders
to IC were treated with 54 Gy of IMRT with cetuximab.
Annual Meeting, and the efficacy data will be presented
at the 2013 American Society of Clinical Oncology An-
nual Meeting.24 The final results of the RTOG are now
eagerly awaited with the hope that a reduced intensity
CRT regimen will provide similar benefits to traditional
platinum-based therapies.
The retrospective nature of this study explains our in-
herent limitations, as does the fairly small sample size
and short follow-up time. Our results should therefore be
interpreted with caution. However, the statistical method-
ology to create a balanced dataset for comparison, utiliz-
ing pairwise matching of the subjects and well-balanced
cohorts, strengthens our work. In particular, propensity
score matching was used to produce a matched dataset of
patients balanced by age, stage, smoking, and tumor HPV
status. This resulted in a reduction of sample size but
allowed for a more accurate analysis.25
The results of our pairwise-matched analysis are inter-
esting and hypothesis-generating, and they imply that a
better-tolerated, organ-preservation approach with a
weekly carboplatin and paclitaxel-based chemoradiation
regimen provides clinical efficacy similar to that of a
more toxic bolus cisplatin chemoradiation protocol. They
also confirm numerous earlier observations of better out-
comes in HPV-related SCCOP. Prospective, randomized
studies evaluating weekly CRT regimens with high-dose
cisplatin and radiation may be warranted in patients with
oropharyngeal cancers, especially if outcomes from
RTOG 1016 and ECOG 1308 fail to demonstrate an
TABLE 3. Toxicity rates in matched datasets.
All-grade toxicities Grade 3–4 toxicities
UMCC 9921 (%) UMCC 0221 (%) p value* UMCC 9921 (%) UMCC 0221 (%) p value*
Leukopenia 25 (71) 6 (17) < .0001 5 (14) 0 (0) .03
Neutropenia 19 (54) 3 (9) < .0001 12 (34) 0 (0) < .0001
Anemia 21 (60) 0 (0) < .0001 1 (3) 0 (0) .50
Thrombopenia 9 (26) 1 (3) .006 1 (3) 1 (3) .51
Nausea 23 (66) 10 (29) .002 3 (9) 3 (9) .33
Vomiting 17 (49) 10 (29) .05 3 (9) 3 (9) .33
Neuropathy 9 (26) 1 (3) .006 0 0
Diarrhea 5 (14) 0 (0) .03 1 (3) 0 (0) .06
Fatigue/weakness 14 (40) 19 (54) .09 1 (3) 1 (3) .51
Mucositis 100% 100% 24 (75) 15 (47) .01
Abbreviation: UMCC, University of Michigan Cancer Center.
*Inestimable in generalized estimating equation model.
TABLE 4. Gastrostomy tube dependence at 6 months after completion of
treatment.
UMCC 9921 (%) UMCC 0221 (%) p value
G-tube 6 mo 9 (26) 2 (6) .05
In HPV positive
(n5 27 pairs)
7 (26) 2 (7) .14
In HPV negative
(n5 8 pairs)
2 (25) 0 (0) .47
Abbreviations: UMCC, University of Michigan Cancer Center; G-tube, gastrostomy tube; HPV,
human papillomavirus.
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advantage with cetuximab-radiotherapy or reduced-inten-
sity radiation with cetuximab.
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